Advent Therapeutics

Advent Therapeutics has extensive expertise and a strong track record in developing respiratory disease products for neonates, children, and niche markets similar to orphan drugs and therapies. Advent is committed to developing life-changing drugs for the most vulnerable preterm infants, focusing on innovative approaches to address the significant unmet medical needs of this underserved "orphan drug" patient population. Advent has developed a proprietary formulation of optimized retinyl palmitate (vitamin A), specifically designed for administration to preterm infants to address vitamin A deficiency and associated severe complications such as bronchopulmonary dysplasia (BPD), retinopathy of prematurity (ROP), and neonatal sepsis, all of which significantly impact short- and long-term clinical outcomes. The company is also exploring the potential of inhalation-optimized retinyl palmitate to mitigate acute lung injury (ALI) and address CBRN (chemical, biological, radiological, and nuclear) threat agents and pulmonary infections (bacterial, influenza, severe acute respiratory syndrome type 2), which often progress to life-threatening acute respiratory distress syndrome (ARDS).